The new Prefense + EtCO2 solution expands capabilities of Nihon Kohden America’s Defensive Monitoring system to safeguard post-surgical patients better
FOOTHILL RANCH, Calif.--(BUSINESS WIRE)-- Nihon Kohden America, a market leader in patient monitoring innovation, has evolved its award-winning Prefense — Early Detection and Notification System to enable hospitals to monitor at-risk, post-surgical patients who are on opioid drips. To achieve this advancement, Nihon Kohden America combined its Cap-STAT mainstream CO2 monitoring technology for intubated and non-intubated patients with its newest Prefense system to enable hospitals to monitor opioid-drip patients for end tidal CO2 (EtCO2), oxygen saturation (SpO2), respiration rate, heart rate and noninvasive blood pressure. This inclusion of EtC02 monitoring to Prefense is the next logical evolution of Nihon Kohden America’s innovative Defensive Monitoring™ system.
Defensive Monitoring was created to safety monitor at-risk patients, and the addition of EtCO2 enhances the capabilities of Prefense to a new level.
“Imagine being able to monitor your post-surgical patients residing on the medical/surgical floors completely, with the freedom to ambulate” said Mike Dashefsky, vice president, Nihon Kohden America. “Now you can. Our new Prefense + EtCO2 system enables you to provide end-to-end monitoring that more fully protects patients, while delivering immediate financial benefits.”
With Prefense, Nihon Kohden America makes it possible — and even affordable — to continuously monitor at-risk patients, not simply those in conventionally monitored areas, such as critical care or telemetry. Prefense goes far beyond the traditional spot-check monitoring strategy. This innovative Defensive Monitoring™ system enables medical personnel to monitor and track trends on vital statistics on a continuous basis via a wireless transmitter, providing advance warning of patient deterioration that is simply unattainable using traditional spot-check technology.
This fifth-generation Prefense system means hospitals can realize:
- Higher patient safety and better patient outcomes
- Improved economics, with better bed utilization and reduced stays
- Fewer unplanned, costly ICU and telemetry admissions
“In the past, monitoring patients’ vital signs continuously has been too expensive to implement in all areas of the hospital,” Dashefsky said. “With Prefense + EtCO2, Nihon Kohden America shatters that objection again. The cost-effectiveness of Prefense allows monitoring to be performed anywhere in the hospital, including those areas where no monitoring takes place currently even though the risk of adverse patient events is high.”
The Nihon Kohden Prefense + EtCO2 system will be on display in booth 804 at ASA 2012, the annual meeting of the American Society of Anesthesiologists, which will be held Oct. 13-15 in Washington, D.C.
About Nihon Kohden America, Patient Monitoring Division
The monitoring division of Nihon Kohden America is empowering hospitals to radically improve their quality and economics of care. Its singular focus is on patient monitoring. Through collaboration with hospitals, Nihon Kohden America helps solve today’s healthcare challenges. This different mindset and business approach enables the company to deliver solutions that have an immediate clinical and financial impact. In addition, Nihon Kohden America is leading the healthcare quality conversation through the sponsorship of Qualnomics, an independent social community dedicated to fostering discussion about the inseparable nature of healthcare quality and its impact on hospital economics. Find more information at www.nkusa.com/monitoring.
Remarx Media for Nihon Kohden America
Cara Stewart, 949-290-5563
Source: Nihon Kohden America